Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
复制标题
DOI：
10.1007/s11892-005-0092-2
复制
发表时间：
2005-10-01
影响因子：
4.2
通讯作者：
Vahl, Torsten P
中科院分区：
文献类型：
--
作者：
D'Alessio, David A;Vahl, Torsten P
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that promotes glucose homeostasis through the regulation of insulin and glucagon secretion, gastric emptying, and food intake. This spectrum of effects makes GLP-1 an attractive candidate for drug development. However, because GLP-1 is a small peptide with rapid metabolism in the circulation, its usefulness to treat patients is limited. However, GLP-1 mimetics that are resistant to degradation have been developed and are effective in lowering blood glucose in diabetic patients. A second strategy for harnessing GLP-1 therapeutically is to inhibit the metabolism of endogenous GLP-1; several orally available compounds are in clinical trials. These two new classes of drugs both enhance GLP-1 signaling but differ in several key characteristics that may lead to distinct roles in the treatment of diabetic patients.
